BMS files for FDA approval of protease inhibitor Zrivada
BY Advocate.com Editors
January 03 2003 1:00 AM ET
Pharmaceutical company Bristol-Myers Squibb this week applied for Food and Drug Administration approval of its experimental second-generation protease inhibitor Zrivada (atazanavir). The FDA application included data from Phase III clinical trials showing that the once-a-day drug is as effective as other protease inhibitors and does not cause blood lipid levels to rise, a problem common with existing protease drugs. More than 2,400 people have participated in studies of Zrivada, which is currently available through an early-access program for patients who have failed other anti-HIV medications. A decision by the FDA is expected by early summer.
- WATCH: Gay Couple Assaulted at Dallas BBQ in Chelsea
- WATCH: Jon Stewart's Mic-Drop on Antigay GOP's 'Slim Chances' at White House
- Drag Race's Trixie Mattel: 'I Actually Thought I Would Win'
- WATCH: Janet Mock Gives Oprah 'Ah-Ha' Moments About Gender
- Meet the Same-Sex Couple Who Made Dodger Stadium Swoon
- WATCH: Nebraska Woman Is Suing All 'Homosexuals' on Behalf of God